However, their study only had a moderate sample size; inaddition, the proportion of patients with KEAP1 and STK11 mutations in the bTMB-low group was higher than that in the bTMB-medium group, and bTMB-low patients may receive more benefit from PD-1/PD-L1 inhibitor therapy due to the higher frequency of STK11 and KEAP1 mutations and a lower tumor burden, thus overestimating the therapeutic efficacy [52]. Here, CD274 is linked to neoplasm.